A375 |
Function assay |
|
75 mins |
|
Inhibition of BRAF V600E mutant-mediated ERK phosphorylation in human A375 cells after 75 mins, IC50=0.015μM |
23398453 |
Sf9 |
Function assay |
|
20 mins |
|
Inhibition of human recombinant N-terminus His-tagged BRAF V600E mutant expressed in Sf9 cells coexpressing CDC37 using biotinylated MEK as substrate and MgCl2 incubated for 20 mins prior to MgCl2 addition measured after 1 hr in presence of 10 uM ATP, IC50=0.034μM |
23398453 |
Sf9 |
Function assay |
|
20 mins |
|
Inhibition of human recombinant N-terminus His-tagged BRAF V600E mutant expressed in Sf9 cells coexpressing CDC37 using biotinylated MEK as substrate and MgCl2 incubated for 20 mins prior to MgCl2 addition measured after 1 hr in presence of 5 mM ATP, IC50=0.27μM |
23398453 |
Sf9 |
Function assay |
|
20 mins |
|
Inhibition of human recombinant N-terminus His-tagged BRAF expressed in Sf9 cells coexpressing CDC37 using biotinylated MEK as substrate and MgCl2 incubated for 20 mins prior to MgCl2 addition measured after 1 hr in presence of 5 mM ATP, IC50=2.64μM |
23398453 |
NIH/3T3 |
Function assay |
|
75 mins |
|
Inhibition of wild type BRAF in mouse NIH/3T3 cells assessed as decrease in ERK phosphorylation after 75 mins by Western blotting analysis |
23398453 |
CCD-1070SK |
Function assay |
|
75 mins |
|
Inhibition of wild type BRAF in human CCD-1070SK cells assessed as decrease in ERK phosphorylation after 75 mins by Western blotting analysis |
23398453 |
MCF7 |
Function assay |
|
75 mins |
|
Inhibition of wild type BRAF in human MCF7 cells assessed as decrease in ERK phosphorylation after 75 mins by Western blotting analysis |
23398453 |
A549 |
Function assay |
|
75 mins |
|
Inhibition of wild type BRAF in human A549 cells assessed as decrease in ERK phosphorylation after 75 mins by Western blotting analysis |
23398453 |
PC3 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human PC3 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
PANC1 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human PANC1 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
NCI-H23 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human NCI-H23 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
NCI-H460 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human NCI-H460 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
Calu6 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human Calu6 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
HCT15 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human HCT15 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
MDA-MB-231 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human MDA-MB-231 cells expressing BRAF G464V mutant after 72 hrs by MTS assay |
23398453 |
SKBR3 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human SKBR3 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
MCF7 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human MCF7 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
HCT116 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human HCT116 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
MDA-MB-468 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human MDA-MB-468 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
A549 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human A549 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
HT-29 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human HT-29 cells expressing BRAF V600E mutant after 72 hrs by MTS assay |
23398453 |
SW620 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human SW620 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
A2058 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human A2058 cells expressing BRAF V600E mutant after 72 hrs by MTS assay |
23398453 |
DU145 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human DU145 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
SK-MEL-24 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human SK-MEL-24 cells expressing BRAF V600E mutant after 72 hrs by MTS assay |
23398453 |
SK-MEL-28 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human SK-MEL-28 cells expressing BRAF V600E mutant after 72 hrs by MTS assay |
23398453 |
SK-MEL-3 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human SK-MEL-3 cells expressing BRAF V600E mutant after 72 hrs by MTS assay |
23398453 |
MALME-3M |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human MALME-3M cells expressing BRAF V600E mutant after 72 hrs by MTS assay |
23398453 |
COLO205 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human COLO205 cells expressing BRAF V600E mutant after 72 hrs by MTS assay |
23398453 |
A375 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by MTS assay |
23398453 |
A375 |
Function assay |
|
75 mins |
|
Inhibition of BRAF V600E mutant in human A375 cells assessed as decrease in ERK phosphorylation after 75 mins by Western blotting analysis |
23398453 |
MiaPaCa |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human MiaPaCa cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
NIH:OVCAR3 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human NIH:OVCAR3 cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
LNCaP-FGC |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human LNCaP-FGC cells expressing wild type BRAF after 72 hrs by MTS assay |
23398453 |
Malme-3M |
Function assay |
|
|
|
Inhibition of B-Raf V600E mutant in human Malme-3M cells assessed as basal ERK phosphorylation, IC50=0.027μM |
24675381 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells |
29435139 |
NB1643 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells |
29435139 |
RD |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells |
29435139 |
ACN |
Growth inhibition assay |
|
|
|
Inhibition of human ACN cell growth in a cell viability assay, IC50=0.0001009μM |
SANGER |
SH-4 |
Growth inhibition assay |
|
|
|
Inhibition of human SH-4 cell growth in a cell viability assay, IC50=0.003009μM |
SANGER |
LB2518-MEL |
Growth inhibition assay |
|
|
|
Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50=0.004758μM |
SANGER |
A101D |
Growth inhibition assay |
|
|
|
Inhibition of human A101D cell growth in a cell viability assay, IC50=0.005819μM |
SANGER |
HT-144 |
Growth inhibition assay |
|
|
|
Inhibition of human HT-144 cell growth in a cell viability assay, IC50=0.006606μM |
SANGER |
SIG-M5 |
Growth inhibition assay |
|
|
|
Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=0.009455μM |
SANGER |
DU-4475 |
Growth inhibition assay |
|
|
|
Inhibition of human DU-4475 cell growth in a cell viability assay, IC50=0.01023μM |
SANGER |
OCI-AML2 |
Growth inhibition assay |
|
|
|
Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50=0.017μM |
SANGER |
COLO-829 |
Growth inhibition assay |
|
|
|
Inhibition of human COLO-829 cell growth in a cell viability assay, IC50=0.02565μM |
SANGER |
PSN1 |
Growth inhibition assay |
|
|
|
Inhibition of human PSN1 cell growth in a cell viability assay, IC50=0.02737μM |
SANGER |
UACC-257 |
Growth inhibition assay |
|
|
|
Inhibition of human UACC-257 cell growth in a cell viability assay, IC50=0.02749μM |
SANGER |
RKO |
Growth inhibition assay |
|
|
|
Inhibition of human RKO cell growth in a cell viability assay, IC50=0.03767μM |
SANGER |
MMAC-SF |
Growth inhibition assay |
|
|
|
Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50=0.04007μM |
SANGER |
Calu-6 |
Growth inhibition assay |
|
|
|
Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=0.05147μM |
SANGER |
LS-513 |
Growth inhibition assay |
|
|
|
Inhibition of human LS-513 cell growth in a cell viability assay, IC50=0.07415μM |
SANGER |
LS-411N |
Growth inhibition assay |
|
|
|
Inhibition of human LS-411N cell growth in a cell viability assay, IC50=0.09161μM |
SANGER |
NOS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=0.09265μM |
SANGER |
SW872 |
Growth inhibition assay |
|
|
|
Inhibition of human SW872 cell growth in a cell viability assay, IC50=0.09648μM |
SANGER |
KMOE-2 |
Growth inhibition assay |
|
|
|
Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50=0.11588μM |
SANGER |
MZ7-mel |
Growth inhibition assay |
|
|
|
Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50=0.11727μM |
SANGER |
CGTH-W-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50=0.1213μM |
SANGER |
CP66-MEL |
Growth inhibition assay |
|
|
|
Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50=0.13176μM |
SANGER |
K5 |
Growth inhibition assay |
|
|
|
Inhibition of human K5 cell growth in a cell viability assay, IC50=0.1342μM |
SANGER |
HL-60 |
Growth inhibition assay |
|
|
|
Inhibition of human HL-60 cell growth in a cell viability assay, IC50=0.15441μM |
SANGER |
ONS-76 |
Growth inhibition assay |
|
|
|
Inhibition of human ONS-76 cell growth in a cell viability assay, IC50=0.16662μM |
SANGER |
NB69 |
Growth inhibition assay |
|
|
|
Inhibition of human NB69 cell growth in a cell viability assay, IC50=0.19131μM |
SANGER |
LAMA-84 |
Growth inhibition assay |
|
|
|
Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=0.19242μM |
SANGER |
EM-2 |
Growth inhibition assay |
|
|
|
Inhibition of human EM-2 cell growth in a cell viability assay, IC50=0.19591μM |
SANGER |
IST-MEL1 |
Growth inhibition assay |
|
|
|
Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50=0.20413μM |
SANGER |
HCC2998 |
Growth inhibition assay |
|
|
|
Inhibition of human HCC2998 cell growth in a cell viability assay, IC50=0.22187μM |
SANGER |
GDM-1 |
Growth inhibition assay |
|
|
|
Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=0.22947μM |
SANGER |
MZ1-PC |
Growth inhibition assay |
|
|
|
Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50=0.27999μM |
SANGER |
BB49-HNC |
Growth inhibition assay |
|
|
|
Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=0.3518μM |
SANGER |
D-392MG |
Growth inhibition assay |
|
|
|
Inhibition of human D-392MG cell growth in a cell viability assay, IC50=0.35607μM |
SANGER |
697 |
Growth inhibition assay |
|
|
|
Inhibition of human 697 cell growth in a cell viability assay, IC50=0.36388μM |
SANGER |
ML-2 |
Growth inhibition assay |
|
|
|
Inhibition of human ML-2 cell growth in a cell viability assay, IC50=0.36886μM |
SANGER |
MEG-01 |
Growth inhibition assay |
|
|
|
Inhibition of human MEG-01 cell growth in a cell viability assay, IC50=0.376μM |
SANGER |
SK-MEL-1 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50=0.38362μM |
SANGER |
KS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human KS-1 cell growth in a cell viability assay, IC50=0.39337μM |
SANGER |
NCI-SNU-1 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50=0.44786μM |
SANGER |
SK-NEP-1 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=0.47226μM |
SANGER |
A4-Fuk |
Growth inhibition assay |
|
|
|
Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50=0.48375μM |
SANGER |
NB14 |
Growth inhibition assay |
|
|
|
Inhibition of human NB14 cell growth in a cell viability assay, IC50=0.49331μM |
SANGER |
NCI-H747 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50=0.50637μM |
SANGER |
K-562 |
Growth inhibition assay |
|
|
|
Inhibition of human K-562 cell growth in a cell viability assay, IC50=0.66695μM |
SANGER |
NCI-H1648 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50=0.67266μM |
SANGER |
LAN-6 |
Growth inhibition assay |
|
|
|
Inhibition of human LAN-6 cell growth in a cell viability assay, IC50=0.68236μM |
SANGER |
BV-173 |
Growth inhibition assay |
|
|
|
Inhibition of human BV-173 cell growth in a cell viability assay, IC50=0.69154μM |
SANGER |
NKM-1 |
Growth inhibition assay |
|
|
|
Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=0.73537μM |
SANGER |
MZ2-MEL |
Growth inhibition assay |
|
|
|
Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50=0.79367μM |
SANGER |
BE-13 |
Growth inhibition assay |
|
|
|
Inhibition of human BE-13 cell growth in a cell viability assay, IC50=0.80575μM |
SANGER |
HUTU-80 |
Growth inhibition assay |
|
|
|
Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=0.98331μM |
SANGER |
CTV-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=1.20065μM |
SANGER |
NOMO-1 |
Growth inhibition assay |
|
|
|
Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50=1.20638μM |
SANGER |
GI-ME-N |
Growth inhibition assay |
|
|
|
Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50=1.29212μM |
SANGER |
TE-12 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-12 cell growth in a cell viability assay, IC50=1.31417μM |
SANGER |
ALL-PO |
Growth inhibition assay |
|
|
|
Inhibition of human ALL-PO cell growth in a cell viability assay, IC50=1.34869μM |
SANGER |
ST486 |
Growth inhibition assay |
|
|
|
Inhibition of human ST486 cell growth in a cell viability assay, IC50=1.38662μM |
SANGER |
MV-4-11 |
Growth inhibition assay |
|
|
|
Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=1.42334μM |
SANGER |
SJSA-1 |
Growth inhibition assay |
|
|
|
Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50=1.43007μM |
SANGER |
LB373-MEL-D |
Growth inhibition assay |
|
|
|
Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50=1.66482μM |
SANGER |
ECC12 |
Growth inhibition assay |
|
|
|
Inhibition of human ECC12 cell growth in a cell viability assay, IC50=1.7149μM |
SANGER |
SUP-T1 |
Growth inhibition assay |
|
|
|
Inhibition of human SUP-T1 cell growth in a cell viability assay, IC50=1.73943μM |
SANGER |
NB5 |
Growth inhibition assay |
|
|
|
Inhibition of human NB5 cell growth in a cell viability assay, IC50=1.95406μM |
SANGER |
BB30-HNC |
Growth inhibition assay |
|
|
|
Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=1.96472μM |
SANGER |
DOHH-2 |
Growth inhibition assay |
|
|
|
Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=1.98728μM |
SANGER |
KM12 |
Growth inhibition assay |
|
|
|
Inhibition of human KM12 cell growth in a cell viability assay, IC50=2.08103μM |
SANGER |
D-502MG |
Growth inhibition assay |
|
|
|
Inhibition of human D-502MG cell growth in a cell viability assay, IC50=2.26142μM |
SANGER |
RPMI-8226 |
Growth inhibition assay |
|
|
|
Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50=2.46647μM |
SANGER |
EW-24 |
Growth inhibition assay |
|
|
|
Inhibition of human EW-24 cell growth in a cell viability assay, IC50=2.71195μM |
SANGER |
TE-441-T |
Growth inhibition assay |
|
|
|
Inhibition of human TE-441-T cell growth in a cell viability assay, IC50=2.80668μM |
SANGER |
NCI-SNU-5 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50=2.81269μM |
SANGER |
BL-70 |
Growth inhibition assay |
|
|
|
Inhibition of human BL-70 cell growth in a cell viability assay, IC50=2.86352μM |
SANGER |
HD-MY-Z |
Growth inhibition assay |
|
|
|
Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50=2.9442μM |
SANGER |
OPM-2 |
Growth inhibition assay |
|
|
|
Inhibition of human OPM-2 cell growth in a cell viability assay, IC50=3.0342μM |
SANGER |
PF-382 |
Growth inhibition assay |
|
|
|
Inhibition of human PF-382 cell growth in a cell viability assay, IC50=3.05237μM |
SANGER |
SK-MEL-2 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50=3.21751μM |
SANGER |
QIMR-WIL |
Growth inhibition assay |
|
|
|
Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=3.23473μM |
SANGER |
LC-1F |
Growth inhibition assay |
|
|
|
Inhibition of human LC-1F cell growth in a cell viability assay, IC50=3.30326μM |
SANGER |
SU-DHL-1 |
Growth inhibition assay |
|
|
|
Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50=3.52915μM |
SANGER |
KG-1 |
Growth inhibition assay |
|
|
|
Inhibition of human KG-1 cell growth in a cell viability assay, IC50=3.80547μM |
SANGER |
MSTO-211H |
Growth inhibition assay |
|
|
|
Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50=3.95028μM |
SANGER |
L-540 |
Growth inhibition assay |
|
|
|
Inhibition of human L-540 cell growth in a cell viability assay, IC50=3.95889μM |
SANGER |
HCC1187 |
Growth inhibition assay |
|
|
|
Inhibition of human HCC1187 cell growth in a cell viability assay, IC50=4.03307μM |
SANGER |
RL95-2 |
Growth inhibition assay |
|
|
|
Inhibition of human RL95-2 cell growth in a cell viability assay, IC50=4.10119μM |
SANGER |
KINGS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50=4.17422μM |
SANGER |
SCC-15 |
Growth inhibition assay |
|
|
|
Inhibition of human SCC-15 cell growth in a cell viability assay, IC50=4.21476μM |
SANGER |
EW-12 |
Growth inhibition assay |
|
|
|
Inhibition of human EW-12 cell growth in a cell viability assay, IC50=4.4199μM |
SANGER |
SIMA |
Growth inhibition assay |
|
|
|
Inhibition of human SIMA cell growth in a cell viability assay, IC50=4.46019μM |
SANGER |
NCI-H720 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50=4.7198μM |
SANGER |
HCC1599 |
Growth inhibition assay |
|
|
|
Inhibition of human HCC1599 cell growth in a cell viability assay, IC50=4.8017μM |
SANGER |
8-MG-BA |
Growth inhibition assay |
|
|
|
Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=4.85156μM |
SANGER |
RPMI-6666 |
Growth inhibition assay |
|
|
|
Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=5.08842μM |
SANGER |
BC-3 |
Growth inhibition assay |
|
|
|
Inhibition of human BC-3 cell growth in a cell viability assay, IC50=5.25452μM |
SANGER |
LB996-RCC |
Growth inhibition assay |
|
|
|
Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50=5.28958μM |
SANGER |
TE-5 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-5 cell growth in a cell viability assay, IC50=5.39519μM |
SANGER |
MPP-89 |
Growth inhibition assay |
|
|
|
Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=5.53594μM |
SANGER |
DJM-1 |
Growth inhibition assay |
|
|
|
Inhibition of human DJM-1 cell growth in a cell viability assay, IC50=5.63516μM |
SANGER |
LC-2-ad |
Growth inhibition assay |
|
|
|
Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50=5.66116μM |
SANGER |
NEC8 |
Growth inhibition assay |
|
|
|
Inhibition of human NEC8 cell growth in a cell viability assay, IC50=5.68736μM |
SANGER |
KGN |
Growth inhibition assay |
|
|
|
Inhibition of human KGN cell growth in a cell viability assay, IC50=5.69705μM |
SANGER |
MOLT-13 |
Growth inhibition assay |
|
|
|
Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50=5.82867μM |
SANGER |
EW-3 |
Growth inhibition assay |
|
|
|
Inhibition of human EW-3 cell growth in a cell viability assay, IC50=5.87026μM |
SANGER |
HOP-62 |
Growth inhibition assay |
|
|
|
Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=6.06751μM |
SANGER |
EW-22 |
Growth inhibition assay |
|
|
|
Inhibition of human EW-22 cell growth in a cell viability assay, IC50=6.09281μM |
SANGER |
EW-11 |
Growth inhibition assay |
|
|
|
Inhibition of human EW-11 cell growth in a cell viability assay, IC50=6.27578μM |
SANGER |
EB2 |
Growth inhibition assay |
|
|
|
Inhibition of human EB2 cell growth in a cell viability assay, IC50=6.33123μM |
SANGER |
TE-9 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-9 cell growth in a cell viability assay, IC50=6.42042μM |
SANGER |
IST-SL2 |
Growth inhibition assay |
|
|
|
Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50=6.51935μM |
SANGER |
GB-1 |
Growth inhibition assay |
|
|
|
Inhibition of human GB-1 cell growth in a cell viability assay, IC50=6.57311μM |
SANGER |
D-247MG |
Growth inhibition assay |
|
|
|
Inhibition of human D-247MG cell growth in a cell viability assay, IC50=6.63417μM |
SANGER |
TK10 |
Growth inhibition assay |
|
|
|
Inhibition of human TK10 cell growth in a cell viability assay, IC50=6.64799μM |
SANGER |
A388 |
Growth inhibition assay |
|
|
|
Inhibition of human A388 cell growth in a cell viability assay, IC50=6.70097μM |
SANGER |
EHEB |
Growth inhibition assay |
|
|
|
Inhibition of human EHEB cell growth in a cell viability assay, IC50=7.13498μM |
SANGER |
ECC4 |
Growth inhibition assay |
|
|
|
Inhibition of human ECC4 cell growth in a cell viability assay, IC50=7.2399μM |
SANGER |
HAL-01 |
Growth inhibition assay |
|
|
|
Inhibition of human HAL-01 cell growth in a cell viability assay, IC50=7.45581μM |
SANGER |
SR |
Growth inhibition assay |
|
|
|
Inhibition of human SR cell growth in a cell viability assay, IC50=7.64918μM |
SANGER |
KU812 |
Growth inhibition assay |
|
|
|
Inhibition of human KU812 cell growth in a cell viability assay, IC50=8.02775μM |
SANGER |
YT |
Growth inhibition assay |
|
|
|
Inhibition of human YT cell growth in a cell viability assay, IC50=8.11695μM |
SANGER |
MOLT-4 |
Growth inhibition assay |
|
|
|
Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=8.51012μM |
SANGER |
SK-UT-1 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50=8.59275μM |
SANGER |
MLMA |
Growth inhibition assay |
|
|
|
Inhibition of human MLMA cell growth in a cell viability assay, IC50=8.65529μM |
SANGER |
MFH-ino |
Growth inhibition assay |
|
|
|
Inhibition of human MFH-ino cell growth in a cell viability assay, IC50=8.9591μM |
SANGER |
IM-9 |
Growth inhibition assay |
|
|
|
Inhibition of human IM-9 cell growth in a cell viability assay, IC50=9.06101μM |
SANGER |
NCI-H322M |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H322M cell growth in a cell viability assay, IC50=9.28598μM |
SANGER |
CESS |
Growth inhibition assay |
|
|
|
Inhibition of human CESS cell growth in a cell viability assay, IC50=9.3786μM |
SANGER |
KE-37 |
Growth inhibition assay |
|
|
|
Inhibition of human KE-37 cell growth in a cell viability assay, IC50=9.49296μM |
SANGER |
U-87-MG |
Growth inhibition assay |
|
|
|
Inhibition of human U-87-MG cell growth in a cell viability assay, IC50=9.78165μM |
SANGER |
EoL-1-cell |
Growth inhibition assay |
|
|
|
Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50=9.93708μM |
SANGER |
CA46 |
Growth inhibition assay |
|
|
|
Inhibition of human CA46 cell growth in a cell viability assay, IC50=10.5081μM |
SANGER |
LB1047-RCC |
Growth inhibition assay |
|
|
|
Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=10.5566μM |
SANGER |
NB1 |
Growth inhibition assay |
|
|
|
Inhibition of human NB1 cell growth in a cell viability assay, IC50=10.5731μM |
SANGER |
LS-123 |
Growth inhibition assay |
|
|
|
Inhibition of human LS-123 cell growth in a cell viability assay, IC50=10.5844μM |
SANGER |
GOTO |
Growth inhibition assay |
|
|
|
Inhibition of human GOTO cell growth in a cell viability assay, IC50=10.966μM |
SANGER |
LB2241-RCC |
Growth inhibition assay |
|
|
|
Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=11.3688μM |
SANGER |
RPMI-8402 |
Growth inhibition assay |
|
|
|
Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50=11.7395μM |
SANGER |
EW-18 |
Growth inhibition assay |
|
|
|
Inhibition of human EW-18 cell growth in a cell viability assay, IC50=12.2119μM |
SANGER |
SF268 |
Growth inhibition assay |
|
|
|
Inhibition of human SF268 cell growth in a cell viability assay, IC50=12.5572μM |
SANGER |
NCI-H2171 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50=12.7506μM |
SANGER |
SCLC-21H |
Growth inhibition assay |
|
|
|
Inhibition of human SCLC-21H cell growth in a cell viability assay, IC50=13.4345μM |
SANGER |
MDA-MB-134-VI |
Growth inhibition assay |
|
|
|
Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay, IC50=13.8879μM |
SANGER |
ES5 |
Growth inhibition assay |
|
|
|
Inhibition of human ES5 cell growth in a cell viability assay, IC50=13.9428μM |
SANGER |
KALS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=14.1325μM |
SANGER |
GI-1 |
Growth inhibition assay |
|
|
|
Inhibition of human GI-1 cell growth in a cell viability assay, IC50=14.1988μM |
SANGER |
U-698-M |
Growth inhibition assay |
|
|
|
Inhibition of human U-698-M cell growth in a cell viability assay, IC50=14.435μM |
SANGER |
LP-1 |
Growth inhibition assay |
|
|
|
Inhibition of human LP-1 cell growth in a cell viability assay, IC50=14.4661μM |
SANGER |
NCI-H23 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H23 cell growth in a cell viability assay, IC50=14.724μM |
SANGER |
HC-1 |
Growth inhibition assay |
|
|
|
Inhibition of human HC-1 cell growth in a cell viability assay, IC50=14.7737μM |
SANGER |
NCI-H1355 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=14.9946μM |
SANGER |
LC4-1 |
Growth inhibition assay |
|
|
|
Inhibition of human LC4-1 cell growth in a cell viability assay, IC50=15.1355μM |
SANGER |
CCRF-CEM |
Growth inhibition assay |
|
|
|
Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=15.2306μM |
SANGER |
TE-1 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-1 cell growth in a cell viability assay, IC50=15.5684μM |
SANGER |
NTERA-S-cl-D1 |
Growth inhibition assay |
|
|
|
Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50=16.395μM |
SANGER |
LOXIMVI |
Growth inhibition assay |
|
|
|
Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50=16.4329μM |
SANGER |
MONO-MAC-6 |
Growth inhibition assay |
|
|
|
Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50=16.6532μM |
SANGER |
NCI-H716 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H716 cell growth in a cell viability assay, IC50=16.9882μM |
SANGER |
JiyoyeP-2003 |
Growth inhibition assay |
|
|
|
Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50=17.2361μM |
SANGER |
SW954 |
Growth inhibition assay |
|
|
|
Inhibition of human SW954 cell growth in a cell viability assay, IC50=17.7495μM |
SANGER |
CAS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=17.7612μM |
SANGER |
SF539 |
Growth inhibition assay |
|
|
|
Inhibition of human SF539 cell growth in a cell viability assay, IC50=17.8653μM |
SANGER |
COLO-800 |
Growth inhibition assay |
|
|
|
Inhibition of human COLO-800 cell growth in a cell viability assay, IC50=18.0144μM |
SANGER |
KY821 |
Growth inhibition assay |
|
|
|
Inhibition of human KY821 cell growth in a cell viability assay, IC50=18.4608μM |
SANGER |
LU-65 |
Growth inhibition assay |
|
|
|
Inhibition of human LU-65 cell growth in a cell viability assay, IC50=18.5947μM |
SANGER |
JVM-2 |
Growth inhibition assay |
|
|
|
Inhibition of human JVM-2 cell growth in a cell viability assay, IC50=18.6058μM |
SANGER |
CRO-AP2 |
Growth inhibition assay |
|
|
|
Inhibition of human CRO-AP2 cell growth in a cell viability assay, IC50=18.6171μM |
SANGER |
NCI-H128 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H128 cell growth in a cell viability assay, IC50=19.2368μM |
SANGER |
AM-38 |
Growth inhibition assay |
|
|
|
Inhibition of human AM-38 cell growth in a cell viability assay, IC50=19.7389μM |
SANGER |
NCI-H64 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H64 cell growth in a cell viability assay, IC50=19.9518μM |
SANGER |
ES6 |
Growth inhibition assay |
|
|
|
Inhibition of human ES6 cell growth in a cell viability assay, IC50=20.3657μM |
SANGER |
KARPAS-45 |
Growth inhibition assay |
|
|
|
Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=20.4183μM |
SANGER |
NCI-H1581 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=20.5843μM |
SANGER |
KURAMOCHI |
Growth inhibition assay |
|
|
|
Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50=20.7537μM |
SANGER |
NALM-6 |
Growth inhibition assay |
|
|
|
Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=21.2955μM |
SANGER |
DSH1 |
Growth inhibition assay |
|
|
|
Inhibition of human DSH1 cell growth in a cell viability assay, IC50=21.3697μM |
SANGER |
Becker |
Growth inhibition assay |
|
|
|
Inhibition of human Becker cell growth in a cell viability assay, IC50=21.5612μM |
SANGER |
HH |
Growth inhibition assay |
|
|
|
Inhibition of human HH cell growth in a cell viability assay, IC50=21.8318μM |
SANGER |
EB-3 |
Growth inhibition assay |
|
|
|
Inhibition of human EB-3 cell growth in a cell viability assay, IC50=21.8562μM |
SANGER |
HCC2157 |
Growth inhibition assay |
|
|
|
Inhibition of human HCC2157 cell growth in a cell viability assay, IC50=22.2184μM |
SANGER |
no-10 |
Growth inhibition assay |
|
|
|
Inhibition of human no-10 cell growth in a cell viability assay, IC50=22.5132μM |
SANGER |
D-263MG |
Growth inhibition assay |
|
|
|
Inhibition of human D-263MG cell growth in a cell viability assay, IC50=22.9998μM |
SANGER |
Raji |
Growth inhibition assay |
|
|
|
Inhibition of human Raji cell growth in a cell viability assay, IC50=23.4081μM |
SANGER |
EKVX |
Growth inhibition assay |
|
|
|
Inhibition of human EKVX cell growth in a cell viability assay, IC50=23.7929μM |
SANGER |
LS-1034 |
Growth inhibition assay |
|
|
|
Inhibition of human LS-1034 cell growth in a cell viability assay, IC50=24.2647μM |
SANGER |
SF126 |
Growth inhibition assay |
|
|
|
Inhibition of human SF126 cell growth in a cell viability assay, IC50=24.9217μM |
SANGER |
MC-CAR |
Growth inhibition assay |
|
|
|
Inhibition of human MC-CAR cell growth in a cell viability assay, IC50=25.0901μM |
SANGER |
RL |
Growth inhibition assay |
|
|
|
Inhibition of human RL cell growth in a cell viability assay, IC50=25.1477μM |
SANGER |
KNS-81-FD |
Growth inhibition assay |
|
|
|
Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50=25.8563μM |
SANGER |
Ramos-2G6-4C10 |
Growth inhibition assay |
|
|
|
Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50=26.0093μM |
SANGER |
TE-8 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-8 cell growth in a cell viability assay, IC50=26.0599μM |
SANGER |
ES8 |
Growth inhibition assay |
|
|
|
Inhibition of human ES8 cell growth in a cell viability assay, IC50=26.1087μM |
SANGER |
SK-PN-DW |
Growth inhibition assay |
|
|
|
Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50=27.3933μM |
SANGER |
NCI-H2126 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50=27.6384μM |
SANGER |
NCI-SNU-16 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-SNU-16 cell growth in a cell viability assay, IC50=27.7795μM |
SANGER |
MHH-PREB-1 |
Growth inhibition assay |
|
|
|
Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50=27.9604μM |
SANGER |
HCE-T |
Growth inhibition assay |
|
|
|
Inhibition of human HCE-T cell growth in a cell viability assay, IC50=29.2587μM |
SANGER |
IST-MES1 |
Growth inhibition assay |
|
|
|
Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50=29.329μM |
SANGER |
CTB-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=31.889μM |
SANGER |
MOLT-16 |
Growth inhibition assay |
|
|
|
Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=32.0214μM |
SANGER |
BC-1 |
Growth inhibition assay |
|
|
|
Inhibition of human BC-1 cell growth in a cell viability assay, IC50=32.527μM |
SANGER |
A253 |
Growth inhibition assay |
|
|
|
Inhibition of human A253 cell growth in a cell viability assay, IC50=32.9626μM |
SANGER |
D-336MG |
Growth inhibition assay |
|
|
|
Inhibition of human D-336MG cell growth in a cell viability assay, IC50=33.9563μM |
SANGER |
KARPAS-422 |
Growth inhibition assay |
|
|
|
Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50=34.5318μM |
SANGER |
BB65-RCC |
Growth inhibition assay |
|
|
|
Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=36.0231μM |
SANGER |
WSU-NHL |
Growth inhibition assay |
|
|
|
Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50=36.1908μM |
SANGER |
COLO-824 |
Growth inhibition assay |
|
|
|
Inhibition of human COLO-824 cell growth in a cell viability assay, IC50=37.3777μM |
SANGER |
COR-L279 |
Growth inhibition assay |
|
|
|
Inhibition of human COR-L279 cell growth in a cell viability assay, IC50=37.3993μM |
SANGER |
SK-N-FI |
Growth inhibition assay |
|
|
|
Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50=38.3192μM |
SANGER |
U-266 |
Growth inhibition assay |
|
|
|
Inhibition of human U-266 cell growth in a cell viability assay, IC50=38.8703μM |
SANGER |
A3-KAW |
Growth inhibition assay |
|
|
|
Inhibition of human A3-KAW cell growth in a cell viability assay, IC50=39.1454μM |
SANGER |
Daudi |
Growth inhibition assay |
|
|
|
Inhibition of human Daudi cell growth in a cell viability assay, IC50=42.5065μM |
SANGER |
NCI-H1092 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50=43.345μM |
SANGER |
NB10 |
Growth inhibition assay |
|
|
|
Inhibition of human NB10 cell growth in a cell viability assay, IC50=43.945μM |
SANGER |
LXF-289 |
Growth inhibition assay |
|
|
|
Inhibition of human LXF-289 cell growth in a cell viability assay, IC50=44.786μM |
SANGER |
MHH-NB-11 |
Growth inhibition assay |
|
|
|
Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50=45.1968μM |
SANGER |
LOUCY |
Growth inhibition assay |
|
|
|
Inhibition of human LOUCY cell growth in a cell viability assay, IC50=45.9997μM |
SANGER |
DMS-114 |
Growth inhibition assay |
|
|
|
Inhibition of human DMS-114 cell growth in a cell viability assay, IC50=46.1196μM |
SANGER |
NCI-H1882 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1882 cell growth in a cell viability assay, IC50=46.5042μM |
SANGER |
ES3 |
Growth inhibition assay |
|
|
|
Inhibition of human ES3 cell growth in a cell viability assay, IC50=46.5616μM |
SANGER |
OCUB-M |
Growth inhibition assay |
|
|
|
Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=46.9249μM |
SANGER |
TGW |
Growth inhibition assay |
|
|
|
Inhibition of human TGW cell growth in a cell viability assay, IC50=47.6222μM |
SANGER |
OS-RC-2 |
Growth inhibition assay |
|
|
|
Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=48.0389μM |
SANGER |
D-542MG |
Growth inhibition assay |
|
|
|
Inhibition of human D-542MG cell growth in a cell viability assay, IC50=49.6469μM |
SANGER |